Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pulmatrix has introduced a novel inhaled dry powder drug delivery platform - iSPERSE for use in the delivery of drugs via inhalation for local or systemic applications.
Subscribe to our email newsletter
The iSPERSE platform enables the delivery of small molecule drugs, drug combinations (including triple drug combinations or higher) and macromolecule drugs at doses well in excess of those achievable by traditional dry powder lactose blend technologies.
Pulmatrix said iSPERSE powders, which comprise proprietary cationic salt formulations, are small in geometric size and relatively dense, yet are highly dispersible and relatively flow rate independent with high emitted doses achieved at low flow rates.
Furthermore, iSPERSE’s proprietary powders allow for flexible formulation with straightforward manufacturing, supporting the formulation of small and large molecule drugs as well drug combinations, including triple drug combinations or higher.
Pulmatrix claims the technology avoids the drug-loading, flow rate sensitivity and low efficiency limitations of conventional lactose blending inhalation technologies.
The company has completed proof-of-concept validation studies of the platform along with initial patent filings.
Pulmatrix has developed a complete range of pulmonary drug formulation capabilities such as dry powder formulation and manufacturing; dry powder physicochemical properties optimization; aerosol characterization and method development; dry powder inhaler selection and testing; preclinical efficacy/safety testing (in vitro/in vivo); and clinical program operation and management, to support the development of its own pipeline as well as the iSPERSE partnering programs.
Pulmatrix CEO Robert Connelly said as they have successfully advanced product candidates from core iCALM platform in multiple human clinical trials, they discovered the science and developed the proprietary know-how and insights that form the basis of their second novel platform, iSPERSE.
"Thus, in additional to our own proprietary iSPERSE drug programs, we are pursuing iSPERSE platform partnering opportunities with the goal of attracting several pharmaceutical partners with interest in a range of commercial opportunities for iSPERSE including: novel drugs, drugs not yet formulated for lung delivery, improved delivery of drugs for better efficacy or safety, multi-drug combinations, and branded generic products," Connelly said.